See every side of every news story
Published loading...Updated

AdventHealth Among First in U.S. to Offer IDP023-2-101 Clinical Trial for Patients with Progressive Multiple Sclerosis

Summary by AdventHealth
The AdventHealth Neuroscience Institute is the first in Florida and one of the first in the country to begin recruiting patients with primary progressive or non-active secondary progressive multiple sclerosis (MS) for a new Phase Ib clinical trial of an investigational drug called IDP-023. The aim...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

AdventHealth broke the news in on Thursday, March 27, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.